-
1
-
-
84862843404
-
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
-
DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379: 2429–2438. doi: 10.1016/S0140-6736(12)60918-0 22748590
-
(2012)
Lancet
, vol.379
, pp. 2429-2438
-
-
DeJesus, E.1
Rockstroh, J.K.2
Henry, K.3
Molina, J.M.4
Gathe, J.5
-
2
-
-
84874411899
-
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
-
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735–743. doi: 10.1016/S0140-6736(12)61853-4 23306000
-
(2013)
Lancet
, vol.381
, pp. 735-743
-
-
Raffi, F.1
Rachlis, A.2
Stellbrink, H.J.3
Hardy, W.D.4
Torti, C.5
-
3
-
-
84937215233
-
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
-
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, et al. (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet.
-
(2015)
Lancet
-
-
Sax, P.E.1
Wohl, D.2
Yin, M.T.3
Post, F.4
DeJesus, E.5
-
4
-
-
0033914367
-
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
-
Chun TW, Davey RT, Jr.Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6: 757–761. 10888923
-
(2000)
Nat Med
, vol.6
, pp. 757-761
-
-
Chun, T.W.1
Davey, R.T.2
Ostrowski, M.3
Shawn Justement, J.4
Engel, D.5
-
5
-
-
15744397757
-
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection
-
Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et al. (2004) Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 1: e64. 15630469
-
(2004)
PLoS Med
, vol.1
, pp. 64
-
-
Papasavvas, E.1
Kostman, J.R.2
Mounzer, K.3
Grant, R.M.4
Gross, R.5
-
6
-
-
34247185027
-
The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure
-
Siliciano JD, Siliciano RF, (2006) The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS 1: 121–128. 19372795
-
(2006)
Curr Opin HIV AIDS
, vol.1
, pp. 121-128
-
-
Siliciano, J.D.1
Siliciano, R.F.2
-
7
-
-
0038579210
-
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
-
Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727–728. 12754504
-
(2003)
Nat Med
, vol.9
, pp. 727-728
-
-
Siliciano, J.D.1
Kajdas, J.2
Finzi, D.3
Quinn, T.C.4
Chadwick, K.5
-
8
-
-
41649083599
-
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
-
Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879–3884. doi: 10.1073/pnas.0800050105 18332425
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 3879-3884
-
-
Palmer, S.1
Maldarelli, F.2
Wiegand, A.3
Bernstein, B.4
Hanna, G.J.5
-
9
-
-
68349139711
-
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
-
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893–900. doi: 10.1038/nm.1972 19543283
-
(2009)
Nat Med
, vol.15
, pp. 893-900
-
-
Chomont, N.1
El-Far, M.2
Ancuta, P.3
Trautmann, L.4
Procopio, F.A.5
-
10
-
-
62249095476
-
The challenge of finding a cure for HIV infection
-
Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304–1307. doi: 10.1126/science.1165706 19265012
-
(2009)
Science
, vol.323
, pp. 1304-1307
-
-
Richman, D.D.1
Margolis, D.M.2
Delaney, M.3
Greene, W.C.4
Hazuda, D.5
-
11
-
-
84880330155
-
HIV-1 eradication strategies: design and assessment
-
Siliciano JD, Siliciano RF, (2013) HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 8: 318–325. 23698561
-
(2013)
Curr Opin HIV AIDS
, vol.8
, pp. 318-325
-
-
Siliciano, J.D.1
Siliciano, R.F.2
-
12
-
-
84864625807
-
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency
-
Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, et al. (2012) Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 8: e1002818. doi: 10.1371/journal.ppat.1002818 22911005
-
(2012)
PLoS Pathog
, vol.8
, pp. 1002818
-
-
Pace, M.J.1
Graf, E.H.2
Agosto, L.M.3
Mexas, A.M.4
Male, F.5
-
13
-
-
84881319698
-
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]
-
Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, et al. (2013) Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One 8: e71879. doi: 10.1371/journal.pone.0071879 23951263
-
(2013)
PLoS One
, vol.8
, pp. 71879
-
-
Graf, E.H.1
Pace, M.J.2
Peterson, B.A.3
Lynch, L.J.4
Chukwulebe, S.B.5
-
14
-
-
84908318948
-
Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy
-
Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, et al. (2014) Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 52: 3944–3951. doi: 10.1128/JCM.02060-14 25187636
-
(2014)
J Clin Microbiol
, vol.52
, pp. 3944-3951
-
-
Cillo, A.R.1
Vagratian, D.2
Bedison, M.A.3
Anderson, E.M.4
Kearney, M.F.5
-
15
-
-
67649148057
-
Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection
-
Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, et al. (2009) Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther 14: 321–330. 19474466
-
(2009)
Antivir Ther
, vol.14
, pp. 321-330
-
-
Tincati, C.1
Biasin, M.2
Bandera, A.3
Violin, M.4
Marchetti, G.5
-
16
-
-
84879318140
-
Immune activation and HIV persistence: implications for curative approaches to HIV infection
-
Klatt NR, Chomont N, Douek DC, Deeks SG, (2013) Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 254: 326–342. doi: 10.1111/imr.12065 23772629
-
(2013)
Immunol Rev
, vol.254
, pp. 326-342
-
-
Klatt, N.R.1
Chomont, N.2
Douek, D.C.3
Deeks, S.G.4
-
17
-
-
79953892744
-
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection
-
Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, et al. (2011) Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 5: 171–186. doi: 10.2217/bmm.11.15 21473720
-
(2011)
Biomark Med
, vol.5
, pp. 171-186
-
-
Lichtfuss, G.F.1
Hoy, J.2
Rajasuriar, R.3
Kramski, M.4
Crowe, S.M.5
-
18
-
-
0345064200
-
Combination antiretroviral therapy and the risk of myocardial infarction
-
Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993–2003. 14627784
-
(2003)
N Engl J Med
, vol.349
, pp. 1993-2003
-
-
Friis-Moller, N.1
Sabin, C.A.2
Weber, R.3
d'Arminio Monforte, A.4
El-Sadr, W.M.5
-
19
-
-
33745078633
-
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion
-
Smit C, Geskus R, Walker S, Sabin C, Coutinho R, et al. (2006) Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 20: 741–749. 16514305
-
(2006)
AIDS
, vol.20
, pp. 741-749
-
-
Smit, C.1
Geskus, R.2
Walker, S.3
Sabin, C.4
Coutinho, R.5
-
20
-
-
47649115323
-
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
-
Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293–299. doi: 10.1016/S0140-6736(08)61113-7 18657708
-
(2008)
Lancet
, vol.372
, pp. 293-299
-
-
-
21
-
-
84911460971
-
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
-
Rasmussen TA, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, et al. (2014) Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet 1: e13–e21. doi: 10.1016/S2352-3018(14)70014-1 26423811
-
(2014)
Lancet
, vol.1
, pp. 13-21
-
-
Rasmussen, T.A.1
Tolstrup, M.2
Brinkmann, C.3
Olesen, R.4
Erikstrup, C.5
-
22
-
-
84941169144
-
TLR7 agonsit GS-9620 activates HIV-1 in PBMCs from HIV-infected patients on cART [Poster]
-
Sloan D, Irrinki A, Tsai A, Kaur J, Lalezari J, Murry J, Cihlar T. TLR7 agonsit GS-9620 activates HIV-1 in PBMCs from HIV-infected patients on cART [Poster]. Conference on Retroviruses and Opportunistic Infections (Seattle, WA), 2015.
-
(2015)
Conference on Retroviruses and Opportunistic Infections Seattle
-
-
Sloan, D.1
Irrinki, A.2
Tsai, A.3
Kaur, J.4
Lalezari, J.5
Murry, J.6
Cihlar, T.7
-
23
-
-
84887626950
-
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
-
Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503: 224–228. doi: 10.1038/nature12744 24172905
-
(2013)
Nature
, vol.503
, pp. 224-228
-
-
Barouch, D.H.1
Whitney, J.B.2
Moldt, B.3
Klein, F.4
Oliveira, T.Y.5
-
24
-
-
84907379431
-
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice
-
Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, et al. (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158: 989–999. doi: 10.1016/j.cell.2014.07.043 25131989
-
(2014)
Cell
, vol.158
, pp. 989-999
-
-
Halper-Stromberg, A.1
Lu, C.L.2
Klein, F.3
Horwitz, J.A.4
Bournazos, S.5
-
25
-
-
84871491706
-
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
-
Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, et al. (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120: 5185–5187. doi: 10.1182/blood-2012-07-441030 23024237
-
(2012)
Blood
, vol.120
, pp. 5185-5187
-
-
Topp, M.S.1
Gokbuget, N.2
Zugmaier, G.3
Degenhard, E.4
Goebeler, M.E.5
-
26
-
-
84916639631
-
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
-
Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, et al. (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32: 4134–4140. doi: 10.1200/JCO.2014.56.3247 25385737
-
(2014)
J Clin Oncol
, vol.32
, pp. 4134-4140
-
-
Topp, M.S.1
Gokbuget, N.2
Zugmaier, G.3
Klappers, P.4
Stelljes, M.5
-
27
-
-
70249112853
-
-
BLINCYTO (blinatumomab) for injection. US Prescribing Information. Amgen Inc. Thousand Oaks, CA. December 2014.
-
(2014)
US Prescribing Information
-
-
-
28
-
-
84949018378
-
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: pre-clinical activity and safety in non–human primates
-
Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: pre-clinical activity and safety in non–human primates. Sci Trans Med. In Press.
-
Sci Trans Med
-
-
Chichili, G.R.1
Huang, L.2
Li, H.3
Burke, S.4
He, L.5
Tang, Q.6
-
29
-
-
77954757304
-
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion
-
Johnson S, Burke S, Huang L, Gorlatov S, Li H, et al. (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 399: 436–449. doi: 10.1016/j.jmb.2010.04.001 20382161
-
(2010)
J Mol Biol
, vol.399
, pp. 436-449
-
-
Johnson, S.1
Burke, S.2
Huang, L.3
Gorlatov, S.4
Li, H.5
-
30
-
-
79955970356
-
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
-
Moore PA, Zhang W, Rainey GJ, Burke S, Li H, et al. (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117: 4542–4551. doi: 10.1182/blood-2010-09-306449 21300981
-
(2011)
Blood
, vol.117
, pp. 4542-4551
-
-
Moore, P.A.1
Zhang, W.2
Rainey, G.J.3
Burke, S.4
Li, H.5
-
31
-
-
84883796903
-
Antibodies in HIV-1 vaccine development and therapy
-
Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204. doi: 10.1126/science.1241144 24031012
-
(2013)
Science
, vol.341
, pp. 1199-1204
-
-
Klein, F.1
Mouquet, H.2
Dosenovic, P.3
Scheid, J.F.4
Scharf, L.5
-
32
-
-
80053132436
-
Broad neutralization coverage of HIV by multiple highly potent antibodies
-
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470. doi: 10.1038/nature10373 21849977
-
(2011)
Nature
, vol.477
, pp. 466-470
-
-
Walker, L.M.1
Huber, M.2
Doores, K.J.3
Falkowska, E.4
Pejchal, R.5
-
33
-
-
84866493348
-
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
-
Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412. doi: 10.1038/nature11544 23151583
-
(2012)
Nature
, vol.491
, pp. 406-412
-
-
Huang, J.1
Ofek, G.2
Laub, L.3
Louder, M.K.4
Doria-Rose, N.A.5
-
34
-
-
0028073184
-
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies
-
Moore JP, McCutchan FE, Poon SW, Mascola J, Liu J, et al. (1994) Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 68: 8350–8364. 7525988
-
(1994)
J Virol
, vol.68
, pp. 8350-8364
-
-
Moore, J.P.1
McCutchan, F.E.2
Poon, S.W.3
Mascola, J.4
Liu, J.5
-
35
-
-
77955093635
-
Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells
-
Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, et al. (2010) Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods 168: 155–161. doi: 10.1016/j.jviromet.2010.05.008 20471426
-
(2010)
J Virol Methods
, vol.168
, pp. 155-161
-
-
Finzi, A.1
Pacheco, B.2
Zeng, X.3
Kwon, Y.D.4
Kwong, P.D.5
-
36
-
-
84919429656
-
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals
-
Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, et al. (2015) The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 89: 545–551. doi: 10.1128/JVI.02868-14 25339767
-
(2015)
J Virol
, vol.89
, pp. 545-551
-
-
Veillette, M.1
Coutu, M.2
Richard, J.3
Batraville, L.A.4
Dagher, O.5
-
37
-
-
79960342938
-
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
-
Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, et al. (2011) An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85: 7029–7036. doi: 10.1128/JVI.00171-11 21543485
-
(2011)
J Virol
, vol.85
, pp. 7029-7036
-
-
Ferrari, G.1
Pollara, J.2
Kozink, D.3
Harms, T.4
Drinker, M.5
-
38
-
-
0037442143
-
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection
-
Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, et al. (2003) In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol 170: 2236–2241. 12574398
-
(2003)
J Immunol
, vol.170
, pp. 2236-2241
-
-
Pincus, S.H.1
Fang, H.2
Wilkinson, R.A.3
Marcotte, T.K.4
Robinson, J.E.5
-
39
-
-
84867136866
-
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates
-
Craig RB, Summa CM, Corti M, Pincus SH, (2012) Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One 7: e46778. doi: 10.1371/journal.pone.0046778 23056448
-
(2012)
PLoS One
, vol.7
, pp. 46778
-
-
Craig, R.B.1
Summa, C.M.2
Corti, M.3
Pincus, S.H.4
-
40
-
-
84871960572
-
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding
-
Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, et al. (2013) Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 110: E69–78. doi: 10.1073/pnas.1217609110 23237851
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 69-78
-
-
Guan, Y.1
Pazgier, M.2
Sajadi, M.M.3
Kamin-Lewis, R.4
Al-Darmarki, S.5
-
41
-
-
84907991957
-
Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection
-
Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, et al. (2014) Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol 88: 12895–12906. doi: 10.1128/JVI.02194-14 25165110
-
(2014)
J Virol
, vol.88
, pp. 12895-12906
-
-
Acharya, P.1
Tolbert, W.D.2
Gohain, N.3
Wu, X.4
Yu, L.5
-
42
-
-
16944363559
-
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
-
Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215–1224. 9359721
-
(1997)
J Infect Dis
, vol.176
, pp. 1215-1224
-
-
Johnson, S.1
Oliver, C.2
Prince, G.A.3
Hemming, V.G.4
Pfarr, D.S.5
-
43
-
-
33144486096
-
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
-
Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515–2528. 16474158
-
(2006)
J Virol
, vol.80
, pp. 2515-2528
-
-
Moore, P.L.1
Crooks, E.T.2
Porter, L.3
Zhu, P.4
Cayanan, C.S.5
-
44
-
-
84891680667
-
Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41
-
Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, et al. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 88: 1249–1258. doi: 10.1128/JVI.02664-13 24227838
-
(2014)
J Virol
, vol.88
, pp. 1249-1258
-
-
Chen, J.1
Frey, G.2
Peng, H.3
Rits-Volloch, S.4
Garrity, J.5
-
45
-
-
84896855620
-
Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity
-
Cimbro R, Gallant TR, Dolan MA, Guzzo C, Zhang P, et al. (2014) Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A 111: 3152–3157. doi: 10.1073/pnas.1314718111 24569807
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 3152-3157
-
-
Cimbro, R.1
Gallant, T.R.2
Dolan, M.A.3
Guzzo, C.4
Zhang, P.5
-
46
-
-
84903173697
-
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits
-
Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, et al. (2014) Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11: 41. doi: 10.1186/1742-4690-11-41 24884783
-
(2014)
Retrovirology
, vol.11
, pp. 41
-
-
Yasmeen, A.1
Ringe, R.2
Derking, R.3
Cupo, A.4
Julien, J.P.5
-
47
-
-
84917705974
-
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex
-
Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, et al. (2014) Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A 111: 17624–17629. doi: 10.1073/pnas.1415789111 25422458
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 17624-17629
-
-
Sok, D.1
van Gils, M.J.2
Pauthner, M.3
Julien, J.P.4
Saye-Francisco, K.L.5
-
48
-
-
57449109484
-
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
-
Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009–1021. doi: 10.1016/j.immuni.2008.10.010 19062316
-
(2008)
Immunity
, vol.29
, pp. 1009-1021
-
-
Migueles, S.A.1
Osborne, C.M.2
Royce, C.3
Compton, A.A.4
Joshi, R.P.5
-
49
-
-
0033780046
-
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding
-
O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074–10080. 11024136
-
(2000)
J Virol
, vol.74
, pp. 10074-10080
-
-
O'Doherty, U.1
Swiggard, W.J.2
Malim, M.H.3
-
50
-
-
84856190985
-
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs
-
Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC, (2012) A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 7: e30176. doi: 10.1371/journal.pone.0030176 22291913
-
(2012)
PLoS One
, vol.7
, pp. 30176
-
-
Lassen, K.G.1
Hebbeler, A.M.2
Bhattacharyya, D.3
Lobritz, M.A.4
Greene, W.C.5
-
51
-
-
0027432552
-
Down-regulation of CD4 molecules by the expression of Nef: a quantitative analysis of CD4 antigens on the cell surfaces
-
Inoue M, Koga Y, Djordjijevic D, Fukuma T, Reddy EP, et al. (1993) Down-regulation of CD4 molecules by the expression of Nef: a quantitative analysis of CD4 antigens on the cell surfaces. Int Immunol 5: 1067–1073. 7902127
-
(1993)
Int Immunol
, vol.5
, pp. 1067-1073
-
-
Inoue, M.1
Koga, Y.2
Djordjijevic, D.3
Fukuma, T.4
Reddy, E.P.5
-
52
-
-
64649103924
-
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
-
Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, et al. (2009) Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214: 441–453. doi: 10.1016/j.imbio.2008.11.014 19157637
-
(2009)
Immunobiology
, vol.214
, pp. 441-453
-
-
Haas, C.1
Krinner, E.2
Brischwein, K.3
Hoffmann, P.4
Lutterbuse, R.5
-
53
-
-
17644385543
-
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
-
Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, et al. (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115: 98–104. 15688411
-
(2005)
Int J Cancer
, vol.115
, pp. 98-104
-
-
Hoffmann, P.1
Hofmeister, R.2
Brischwein, K.3
Brandl, C.4
Crommer, S.5
-
54
-
-
84928405730
-
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
-
Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr.et al. (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522: 487–491. doi: 10.1038/nature14411 25855300
-
(2015)
Nature
, vol.522
, pp. 487-491
-
-
Caskey, M.1
Klein, F.2
Lorenzi, J.C.3
Seaman, M.S.4
West, A.P.5
-
55
-
-
84901309171
-
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing
-
Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10: e1004071. doi: 10.1371/journal.ppat.1004071 24722454
-
(2014)
PLoS Pathog
, vol.10
, pp. 1004071
-
-
Wei, D.G.1
Chiang, V.2
Fyne, E.3
Balakrishnan, M.4
Barnes, T.5
-
56
-
-
0034712195
-
In vitro characterization of five humanized OKT3 effector function variant antibodies
-
Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, et al. (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200: 16–26. 10716879
-
(2000)
Cell Immunol
, vol.200
, pp. 16-26
-
-
Xu, D.1
Alegre, M.L.2
Varga, S.S.3
Rothermel, A.L.4
Collins, A.M.5
-
57
-
-
84948946365
-
MGD011, humanized CD19 x CD3 DART protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated anti-tumor activity in preclinical models and durable B-cell depletion in cynomolgus monkeys following once-a-week dosing
-
Liu L, Lam A, Alderson R, Yang Y, Li H, Long V, et al. (2014) MGD011, humanized CD19 x CD3 DART protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated anti-tumor activity in preclinical models and durable B-cell depletion in cynomolgus monkeys following once-a-week dosing. Blood 124: 1775.
-
(2014)
Blood
, vol.124
, pp. 1775
-
-
Liu, L.1
Lam, A.2
Alderson, R.3
Yang, Y.4
Li, H.5
Long, V.6
-
58
-
-
84891627700
-
Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies
-
Proetzel G, Roopenian DC, (2014) Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65: 148–153. doi: 10.1016/j.ymeth.2013.07.005 23867339
-
(2014)
Methods
, vol.65
, pp. 148-153
-
-
Proetzel, G.1
Roopenian, D.C.2
-
59
-
-
84877898507
-
Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities
-
Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ, (2013) Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 5: 397–405. doi: 10.4161/mabs.23836 23549129
-
(2013)
MAbs
, vol.5
, pp. 397-405
-
-
Tam, S.H.1
McCarthy, S.G.2
Brosnan, K.3
Goldberg, K.M.4
Scallon, B.J.5
-
60
-
-
84939625364
-
Longitudinal genetic characterization reveals that cell proliferation maintains a persistent HIV type 1 DNA pool during effective HIV therapy
-
von Stockenstrom S, Odevall L, Lee E, Sinclair E, Bacchetti P, Killian M, et al. Longitudinal genetic characterization reveals that cell proliferation maintains a persistent HIV type 1 DNA pool during effective HIV therapy. J Infect Dis. 2015 Feb 23. pii: jiv092. [Epub ahead of print]
-
(2015)
J Infect Dis
, vol.pii
, pp. 92
-
-
von Stockenstrom, S.1
Odevall, L.2
Lee, E.3
Sinclair, E.4
Bacchetti, P.5
Killian, M.6
-
61
-
-
84886790685
-
The end of AIDS: HIV infection as a chronic disease
-
Deeks SG, Lewin SR, Havlir DV, (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382: 1525–1533. doi: 10.1016/S0140-6736(13)61809-7 24152939
-
(2013)
Lancet
, vol.382
, pp. 1525-1533
-
-
Deeks, S.G.1
Lewin, S.R.2
Havlir, D.V.3
-
62
-
-
84885338257
-
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
-
Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, et al. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 110: 16538–16543. doi: 10.1073/pnas.1315295110 24043801
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 16538-16543
-
-
Horwitz, J.A.1
Halper-Stromberg, A.2
Mouquet, H.3
Gitlin, A.D.4
Tretiakova, A.5
-
63
-
-
84887627657
-
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
-
Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, et al. (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503: 277–280. doi: 10.1038/nature12746 24172896
-
(2013)
Nature
, vol.503
, pp. 277-280
-
-
Shingai, M.1
Nishimura, Y.2
Klein, F.3
Mouquet, H.4
Donau, O.K.5
-
64
-
-
84875529000
-
Control of human viral infections by natural killer cells
-
Jost S, Altfeld M, (2013) Control of human viral infections by natural killer cells. Annu Rev Immunol 31: 163–194. doi: 10.1146/annurev-immunol-032712-100001 23298212
-
(2013)
Annu Rev Immunol
, vol.31
, pp. 163-194
-
-
Jost, S.1
Altfeld, M.2
-
65
-
-
37549036732
-
Fcgamma receptors as regulators of immune responses
-
Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34–47. 18064051
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 34-47
-
-
Nimmerjahn, F.1
Ravetch, J.V.2
-
66
-
-
84883368011
-
New paradigms for functional HIV-specific nonneutralizing antibodies
-
Forthal D, Hope TJ, Alter G, (2013) New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS 8: 393–401. 23924999
-
(2013)
Curr Opin HIV AIDS
, vol.8
, pp. 393-401
-
-
Forthal, D.1
Hope, T.J.2
Alter, G.3
-
67
-
-
84883774338
-
Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils
-
Smalls-Mantey A, Connors M, Sattentau QJ, (2013) Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLoS One 8: e74858. doi: 10.1371/journal.pone.0074858 24040353
-
(2013)
PLoS One
, vol.8
, pp. 74858
-
-
Smalls-Mantey, A.1
Connors, M.2
Sattentau, Q.J.3
-
68
-
-
84880329495
-
Progress in HIV-1 vaccine development
-
Haynes BF, McElrath MJ, (2013) Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 8: 326–332. 23743722
-
(2013)
Curr Opin HIV AIDS
, vol.8
, pp. 326-332
-
-
Haynes, B.F.1
McElrath, M.J.2
-
69
-
-
84889849596
-
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
-
Wong R, Pepper C, Brennan P, Nagorsen D, Man S, et al. (2013) Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 98: 1930–1938. doi: 10.3324/haematol.2012.082248 23812940
-
(2013)
Haematologica
, vol.98
, pp. 1930-1938
-
-
Wong, R.1
Pepper, C.2
Brennan, P.3
Nagorsen, D.4
Man, S.5
-
70
-
-
79955662260
-
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
-
Nagorsen D, Baeuerle PA, (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317: 1255–1260. doi: 10.1016/j.yexcr.2011.03.010 21419116
-
(2011)
Exp Cell Res
, vol.317
, pp. 1255-1260
-
-
Nagorsen, D.1
Baeuerle, P.A.2
-
71
-
-
67349241946
-
Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies
-
Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, et al. (2009) Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54: 164–182. doi: 10.1016/j.yrtph.2009.03.012 19345250
-
(2009)
Regul Toxicol Pharmacol
, vol.54
, pp. 164-182
-
-
Ponce, R.1
Abad, L.2
Amaravadi, L.3
Gelzleichter, T.4
Gore, E.5
-
72
-
-
79955979077
-
DARTs take aim at BiTEs
-
Rader C, (2011) DARTs take aim at BiTEs. Blood 117: 4403–4404. doi: 10.1182/blood-2011-02-337691 21527536
-
(2011)
Blood
, vol.117
, pp. 4403-4404
-
-
Rader, C.1
-
73
-
-
84930373269
-
Why HIV virions have low numbers of envelope spikes: implications for vaccine development
-
Schiller J, Chackerian B, (2014) Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog 10: e1004254. doi: 10.1371/journal.ppat.1004254 25101974
-
(2014)
PLoS Pathog
, vol.10
, pp. 1004254
-
-
Schiller, J.1
Chackerian, B.2
-
74
-
-
77954752400
-
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers
-
Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, et al. (2010) Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 51: 233–238. doi: 10.1086/653677 20550452
-
(2010)
Clin Infect Dis
, vol.51
, pp. 233-238
-
-
Julg, B.1
Pereyra, F.2
Buzon, M.J.3
Piechocka-Trocha, A.4
Clark, M.J.5
-
75
-
-
34548689151
-
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
-
Deeks SG, Walker BD, (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406–416. 17892849
-
(2007)
Immunity
, vol.27
, pp. 406-416
-
-
Deeks, S.G.1
Walker, B.D.2
-
76
-
-
0034600786
-
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
-
Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, et al. (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63–75. 10880527
-
(2000)
J Exp Med
, vol.192
, pp. 63-75
-
-
Appay, V.1
Nixon, D.F.2
Donahoe, S.M.3
Gillespie, G.M.4
Dong, T.5
-
77
-
-
84902294112
-
Immunosenescence and aging in HIV
-
Tsoukas C, (2014) Immunosenescence and aging in HIV. Curr Opin HIV AIDS 9: 398–404. doi: 10.1097/COH.0000000000000077 24840059
-
(2014)
Curr Opin HIV AIDS
, vol.9
, pp. 398-404
-
-
Tsoukas, C.1
-
78
-
-
84922764937
-
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
-
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, et al. (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381–385. doi: 10.1038/nature14053 25561180
-
(2015)
Nature
, vol.517
, pp. 381-385
-
-
Deng, K.1
Pertea, M.2
Rongvaux, A.3
Wang, L.4
Durand, C.M.5
-
79
-
-
0037213278
-
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies
-
Poignard P, Moulard M, Golez E, Vivona V, Franti M, et al. (2003) Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 77: 353–365. 12477840
-
(2003)
J Virol
, vol.77
, pp. 353-365
-
-
Poignard, P.1
Moulard, M.2
Golez, E.3
Vivona, V.4
Franti, M.5
-
80
-
-
84890859441
-
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer
-
Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342: 1484–1490. doi: 10.1126/science.1245627 24179160
-
(2013)
Science
, vol.342
, pp. 1484-1490
-
-
Lyumkis, D.1
Julien, J.P.2
de Val, N.3
Cupo, A.4
Potter, C.S.5
-
81
-
-
77954943648
-
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
-
Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817. doi: 10.1126/science.1192819 20616231
-
(2010)
Science
, vol.329
, pp. 811-817
-
-
Zhou, T.1
Georgiev, I.2
Wu, X.3
Yang, Z.Y.4
Dai, K.5
-
82
-
-
84900467984
-
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers
-
Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, et al. (2014) Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40: 669–680. doi: 10.1016/j.immuni.2014.04.008 24768348
-
(2014)
Immunity
, vol.40
, pp. 669-680
-
-
Blattner, C.1
Lee, J.H.2
Sliepen, K.3
Derking, R.4
Falkowska, E.5
-
83
-
-
84866495323
-
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
-
Kwong PD, Mascola JR, (2012) Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37: 412–425. doi: 10.1016/j.immuni.2012.08.012 22999947
-
(2012)
Immunity
, vol.37
, pp. 412-425
-
-
Kwong, P.D.1
Mascola, J.R.2
-
85
-
-
84878430727
-
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
-
Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, et al. (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110: 9019–9024. doi: 10.1073/pnas.1301456110 23661056
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 9019-9024
-
-
Tomaras, G.D.1
Ferrari, G.2
Shen, X.3
Alam, S.M.4
Liao, H.X.5
-
86
-
-
84867902474
-
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
-
Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, et al. (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86: 11521–11532. doi: 10.1128/JVI.01023-12 22896626
-
(2012)
J Virol
, vol.86
, pp. 11521-11532
-
-
Bonsignori, M.1
Pollara, J.2
Moody, M.A.3
Alpert, M.D.4
Chen, X.5
-
87
-
-
84886769508
-
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
-
Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155: 540–551. doi: 10.1016/j.cell.2013.09.020 24243014
-
(2013)
Cell
, vol.155
, pp. 540-551
-
-
Ho, Y.C.1
Shan, L.2
Hosmane, N.N.3
Wang, J.4
Laskey, S.B.5
-
88
-
-
84900473405
-
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
-
Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Jr.et al. (2014) Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111: 7078–7083. doi: 10.1073/pnas.1402873111 24706775
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 7078-7083
-
-
Cillo, A.R.1
Sobolewski, M.D.2
Bosch, R.J.3
Fyne, E.4
Piatak, M.5
-
89
-
-
84928986546
-
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
-
Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, et al. (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125: 1901–1912. doi: 10.1172/JCI80142 25822022
-
(2015)
J Clin Invest
, vol.125
, pp. 1901-1912
-
-
Laird, G.M.1
Bullen, C.K.2
Rosenbloom, D.I.3
Martin, A.R.4
Hill, A.L.5
-
90
-
-
84898423894
-
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
-
Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF, (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20: 425–429. doi: 10.1038/nm.3489 24658076
-
(2014)
Nat Med
, vol.20
, pp. 425-429
-
-
Bullen, C.K.1
Laird, G.M.2
Durand, C.M.3
Siliciano, J.D.4
Siliciano, R.F.5
-
91
-
-
84938795129
-
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
-
Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, et al. (2015) An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 11: e1005063. doi: 10.1371/journal.ppat.1005063 26225566
-
(2015)
PLoS Pathog
, vol.11
, pp. 1005063
-
-
Darcis, G.1
Kula, A.2
Bouchat, S.3
Fujinaga, K.4
Corazza, F.5
-
92
-
-
0036315848
-
Effects of prostratin on T-cell activation and human immunodeficiency virus latency
-
Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA, (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76: 8118–8123. 12134017
-
(2002)
J Virol
, vol.76
, pp. 8118-8123
-
-
Korin, Y.D.1
Brooks, D.G.2
Brown, S.3
Korotzer, A.4
Zack, J.A.5
-
93
-
-
0035873711
-
Protein kinase C-theta mediates a selective T cell survival signal via phosphorylation of BAD
-
Villalba M, Bushway P, Altman A, (2001) Protein kinase C-theta mediates a selective T cell survival signal via phosphorylation of BAD. J Immunol 166: 5955–5963. 11342610
-
(2001)
J Immunol
, vol.166
, pp. 5955-5963
-
-
Villalba, M.1
Bushway, P.2
Altman, A.3
-
94
-
-
0032728434
-
Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells
-
Ruiz-Ruiz C, Robledo G, Font J, Izquierdo M, Lopez-Rivas A, (1999) Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells. J Immunol 163: 4737–4746. 10528172
-
(1999)
J Immunol
, vol.163
, pp. 4737-4746
-
-
Ruiz-Ruiz, C.1
Robledo, G.2
Font, J.3
Izquierdo, M.4
Lopez-Rivas, A.5
-
95
-
-
0037020082
-
Designing heterodimeric two-stranded alpha-helical coiled-coils. Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity
-
Litowski JR, Hodges RS, (2002) Designing heterodimeric two-stranded alpha-helical coiled-coils. Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity. J Biol Chem 277: 37272–37279. 12138097
-
(2002)
J Biol Chem
, vol.277
, pp. 37272-37279
-
-
Litowski, J.R.1
Hodges, R.S.2
|